Tags

Type your tag names separated by a space and hit enter

Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia.
J Pain Symptom Manage. 1997 Jul; 14(1):7-14.JP

Abstract

We studied the effects of long-term (12 months) dronabinol in 94 late-stage acquired immunodeficiency syndrome (AIDS) patients (mean CD4 count of 45/mm3) who previously participated in a 6-week study (placebo versus dronabinol). All patients received dronabinol orally-2.5 mg twice daily (90%) or 2.5 mg once daily (10%). Appetite was measured using a visual analogue scale for hunger (VASH). Dronabinol was associated with consistent improvement in mean appetite. Patients previously treated with dronabinol continued to show improvement in VASH (percent change from baseline of 6-week trial: 48.6-76.1% at each month), whereas those previously treated with placebo exhibited substantial improvement in mean appetite, particularly during the initial 4 months of treatment (48.5-69.9%). Thereafter, dronabinol was associated with a VASH change at least twice baseline. Patients tended toward stable body weight for at least 7 months. Adverse events were primarily related to known central nervous system effects of dronabinol. These data support long-term, safe use of dronabinol for anorexia associated with weight loss in patients with AIDS.

Authors+Show Affiliations

St. John's Hospital, Tulsa, Oklahoma, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9223837

Citation

Beal, J E., et al. "Long-term Efficacy and Safety of Dronabinol for Acquired Immunodeficiency Syndrome-associated Anorexia." Journal of Pain and Symptom Management, vol. 14, no. 1, 1997, pp. 7-14.
Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage. 1997;14(1):7-14.
Beal, J. E., Olson, R., Lefkowitz, L., Laubenstein, L., Bellman, P., Yangco, B., Morales, J. O., Murphy, R., Powderly, W., Plasse, T. F., Mosdell, K. W., & Shepard, K. V. (1997). Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. Journal of Pain and Symptom Management, 14(1), 7-14.
Beal JE, et al. Long-term Efficacy and Safety of Dronabinol for Acquired Immunodeficiency Syndrome-associated Anorexia. J Pain Symptom Manage. 1997;14(1):7-14. PubMed PMID: 9223837.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. AU - Beal,J E, AU - Olson,R, AU - Lefkowitz,L, AU - Laubenstein,L, AU - Bellman,P, AU - Yangco,B, AU - Morales,J O, AU - Murphy,R, AU - Powderly,W, AU - Plasse,T F, AU - Mosdell,K W, AU - Shepard,K V, PY - 1997/7/1/pubmed PY - 1997/7/1/medline PY - 1997/7/1/entrez SP - 7 EP - 14 JF - Journal of pain and symptom management JO - J Pain Symptom Manage VL - 14 IS - 1 N2 - We studied the effects of long-term (12 months) dronabinol in 94 late-stage acquired immunodeficiency syndrome (AIDS) patients (mean CD4 count of 45/mm3) who previously participated in a 6-week study (placebo versus dronabinol). All patients received dronabinol orally-2.5 mg twice daily (90%) or 2.5 mg once daily (10%). Appetite was measured using a visual analogue scale for hunger (VASH). Dronabinol was associated with consistent improvement in mean appetite. Patients previously treated with dronabinol continued to show improvement in VASH (percent change from baseline of 6-week trial: 48.6-76.1% at each month), whereas those previously treated with placebo exhibited substantial improvement in mean appetite, particularly during the initial 4 months of treatment (48.5-69.9%). Thereafter, dronabinol was associated with a VASH change at least twice baseline. Patients tended toward stable body weight for at least 7 months. Adverse events were primarily related to known central nervous system effects of dronabinol. These data support long-term, safe use of dronabinol for anorexia associated with weight loss in patients with AIDS. SN - 0885-3924 UR - https://www.unboundmedicine.com/medline/citation/9223837/Long_term_efficacy_and_safety_of_dronabinol_for_acquired_immunodeficiency_syndrome_associated_anorexia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0885-3924(97)00038-9 DB - PRIME DP - Unbound Medicine ER -